Exelixis, Inc. (NASDAQ:EXEL)

CAPS Rating: 4 out of 5

A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.

Recs

0
Player Avatar pchop123 (78.31) Submitted: 11/21/2012 4:48:32 PM : Outperform Start Price: $5.27 EXEL Score: -8.35

like the short term prospects here at this price especially

Featured Broker Partners


Advertisement